# F-star Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/f-star-biotechnology

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.f-star.com
- Total disclosed funding: $35M
- Latest round: Series A (Oct 23, 2013)
- Investors on record: 7

## About

F-star Biotechnology Limited, based in the UK, focuses on developing innovative multispecific antibody therapeutics to enhance cancer treatment through proprietary bispecific antibody formats.F-star Biotechnology Limited specializes in the development of multispecific antibody therapeutics. Founded in 2006 and headquartered in Cambridge, UK, the company has undergone significant strategic changes including its latest Trade Sale in June 2022, where it was acquired by invoX Pharma Limited for USD 161.00 mn. Prior to this acquisition, F-star had completed 9 deals, marking its impactful presence in the biotechnology sector. The company was delisted from the NASDAQ market following the acquisition completion in March 2023.F-star Therapeutics Ltd. specializes in the development of next-generation multispecific antibody therapeutics, particularly focusing on its proprietary tetravalent bispecific antibody format. This innovative approach allows for the simultaneous targeting of multiple antigens, enhancing the activation of the immune system in patients suffering from cancer and other serious diseases. The company’s advanced pipeline includes first-in-class and best-in-class drug candidates designed to collaborate with a patient's immune system, targeting hard-to-treat cancers to improve patient quality of life and longevity. F-star's products primarily cater to the global oncology market, serving diverse patient populations in North America, Europe, and parts of Asia, where access to innovative cancer therapies is critical.F-star Therapeutics Ltd. reported a revenue of USD 27.95 mn for the year 2019, alongside an EBITDA of USD -48.87 mn. The company generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions, focusing on the development and commercialization of its bispecific antibody therapeutics. Its transaction structures typically involve strategic alliances including licensing agreements and co-development partnerships, allowing for shared risks and resources in drug development. Revenue is driven by milestone payments, royalties on product sales, and potential upfront fees associated with partnership agreements, reflecting the company's contributions to the immunotherapy field.In June 2022, invoX Pharma Limited agreed to acquire F-star Biotechnology Limited for approximately USD 161.00 mn, a transaction completed in March 2023. This acquisition will support the development of Sino Biopharm’s International Biopharmaceutical R&D Platform, facilitating F-star’s future expansions. The company aims to leverage its innovative bispecific antibody therapeutics to penetrate new markets, particularly focusing on increasing access to therapies in Asia while also consolidating its presence in North America and Europe. The recent funding will be instrumental in advancing clinical trials and supporting the launch of new products aimed at addressing unmet medical needs in oncology.

## Funding rounds

- Series A, Oct 23, 2013, $13M — Atlas Venture, TVM Capital Life Science, SR One, Aescap Venture, M Ventures, MP Healthcare Venture Management
- Series A, Jan 6, 2010, $11M — Atlas Venture, TVM Capital Life Science, Novo Holdings, Aescap Venture, M Ventures, MP Healthcare Venture Management
- Series A, Sep 10, 2007, $8.5M — Atlas Venture, Aescap Venture
- Seed, Jan 8, 2007, $2M — Atlas Venture
- Seed, Jun 1, 2006 — Atlas Venture

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A
- Aescap Venture (https://capitalatlas.ai/funds/aescap-venture) — Series A
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A
- Novo Holdings — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A